Patents by Inventor Mohammad Azab

Mohammad Azab has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LOW DOSE COMBINATION CDA SUBSTRATE DRUG/CEDAZURIDINE WITH EXTENDED ADMINISTRATION
    Publication number: 20230270771
    Abstract: This invention relates to methods and compositions for administering an effective amount of a CDA substrate drug and an effective amount of cedazuridine. In particular, the invention relates to methods for treating cancer, inhibiting degradation of a CDA substrate drug, and reducing DNA methylation in a subject in need thereof comprising administering an effective amount of a CDA substrate drug and an effective amount of cedazuridine.
    Type: Application
    Filed: April 21, 2023
    Publication date: August 31, 2023
    Inventors: Harold Keer, Mohammad Azab, Aram Oganesian
  • Low dose combination CDA substrate drug/cedazuridine with extended administration
    Patent number: 11660310
    Abstract: This invention relates to methods and compositions for administering an effective amount of a CDA substrate drug and an effective amount of cedazuridine. In particular, the invention relates to methods for treating cancer, inhibiting degradation of a CDA substrate drug, and reducing DNA methylation in a subject in need thereof comprising administering an effective amount of a CDA substrate drug and an effective amount of cedazuridine.
    Type: Grant
    Filed: December 23, 2021
    Date of Patent: May 30, 2023
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Harold Keer, Mohammad Azab, Aram Oganesian
  • LOW DOSE COMBINATION CDA SUBSTRATE DRUG/CEDAZURIDINE WITH EXTENDED ADMINISTRATION
    Publication number: 20220110958
    Abstract: This invention relates to methods and compositions for administering an effective amount of a CDA substrate drug and an effective amount of cedazuridine. In particular, the invention relates to methods for treating cancer, inhibiting degradation of a CDA substrate drug, and reducing DNA methylation in a subject in need thereof comprising administering an effective amount of a CDA substrate drug and an effective amount of cedazuridine.
    Type: Application
    Filed: December 23, 2021
    Publication date: April 14, 2022
    Inventors: Harold Keer, Mohammad Azab, Aram Oganesian
  • Low dose combination CDA substrate drug/cedazuridine with extended administration
    Patent number: 11224610
    Abstract: This invention relates to methods and compositions for administering an effective amount of a CDA substrate drug and an effective amount of cedazuridine. In particular, the invention relates to methods for treating cancer, inhibiting degradation of a CDA substrate drug, and reducing DNA methylation in a subject in need thereof comprising administering an effective amount of a CDA substrate drug and an effective amount of cedazuridine.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: January 18, 2022
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Harold Keer, Mohammad Azab, Aram Oganesian
  • HYPOMETHYLATING AGENTS FOR USE IN TREATMENT OF CANCER
    Publication number: 20200352976
    Abstract: Disclosed herein is a method for treating cancer with DNA-hypomethylating agents. Also disclosed herein is a method of selecting a treatment for a subject. Treatment can be given to a subject for more than one cycle of treatment to obtain improved efficacy of the treatment.
    Type: Application
    Filed: May 5, 2020
    Publication date: November 12, 2020
    Inventors: Mohammad AZAB, Yong HAO, Harold KEER
  • LOW DOSE COMBINATION CDA SUBSTRATE DRUG/CEDAZURIDINE WITH EXTENDED ADMINISTRATION
    Publication number: 20200085848
    Abstract: This invention relates to methods and compositions for administering an effective amount of a CDA substrate drug and an effective amount of cedazuridine. In particular, the invention relates to methods for treating cancer, inhibiting degradation of a CDA substrate drug, and reducing DNA methylation in a subject in need thereof comprising administering an effective amount of a CDA substrate drug and an effective amount of cedazuridine.
    Type: Application
    Filed: September 18, 2019
    Publication date: March 19, 2020
    Inventors: Harold Keer, Mohammad Azab, Aram Oganesian
  • DRUG COMBINATIONS
    Publication number: 20200009247
    Abstract: The invention provides combinations of derivatives of decitabine and other active agents, including T-cell activating agents, cancer vaccines, and adjuvants. Some derivatives of decitabine exhibit superior chemical stability and shelf life, with similar physiological activity. Methods of treating one or more myelodysplasia syndromes, cancers, haematological disorders, or diseases associated with abnormal haemoglobin synthesis using the combinations are described.
    Type: Application
    Filed: July 17, 2019
    Publication date: January 9, 2020
    Inventors: Mohammad AZAB, Pietro TAVERNA, Alessia COVRE, Sandra CORAL
  • DRUG COMBINATIONS
    Publication number: 20160015805
    Abstract: The invention provides combinations of derivatives of decitabine and other active agents, including T-cell activating agents, cancer vaccines, and adjuvants. Some derivatives of decitabine exhibit superior chemical stability and shelf life, with similar physiological activity. Methods of treating one or more myelodysplasia syndromes, cancers, haematological disorders, or diseases associated with abnormal haemoglobin synthesis using the combinations are described.
    Type: Application
    Filed: February 27, 2014
    Publication date: January 21, 2016
    Inventors: Mohammad AZAB, Pietro TAVERNA, Alessia COVRE, Sandra CORAL
  • Photodynamic therapy of occult age-related macular degeneration
    Patent number: 8034803
    Abstract: The invention relates to the selection and treatment of subjects afflicted with occult choroidal neovascular lesions, including subjects with age-related macular degeneration, by use of photo dynamic therapy (PDT).
    Type: Grant
    Filed: February 6, 2002
    Date of Patent: October 11, 2011
    Assignees: QLT Inc., Novartis, A.G.
    Inventors: H. Andrew Strong, Mohammad Azab, Yong Hao, John Miller Koester, Troy Albert Reaves, Jr.
  • Method to prevent vision loss
    Patent number: 7060695
    Abstract: An improved method to treat conditions of the eye characterized by ocular neovascularization is provided in which patients are given and initial photodynamic therapy (PDT) treatment to destroy the neovasculature, and then are re-evaluated at least twice during the following 6 months, and retreated as necessary. Preferably, three retreatments are provided.
    Type: Grant
    Filed: February 6, 2002
    Date of Patent: June 13, 2006
    Assignees: QLT, Inc., Novartis AG
    Inventors: H. Andrew Strong, Mohammad Azab, Troy Albert Reaves, Jr.
  • Photodynamic therapy of occult age-related macular degeneration
    Publication number: 20030087889
    Abstract: The invention relates to the selection and treatment of subjects afflicted with occult choroidal neovascular lesions, including subjects with age-related macular degeneration, by use of photo dynamic therapy (PDT).
    Type: Application
    Filed: February 6, 2002
    Publication date: May 8, 2003
    Inventors: H. Andrew Strong, Mohammad Azab, Yong Hao, John Miller Koester, Troy Albert Reaves
  • Method to prevent vision loss
    Publication number: 20020183302
    Abstract: An improved method to treat conditions of the eye characterized by ocular neovascularization is provided in which patients are given and initial photodynamic therapy (PDT) treatment to destroy the neovasculature, and then are re-evaluated at least twice during the following 6 months, and retreated as necessary. Preferably, three retreatments are provided.
    Type: Application
    Filed: February 6, 2002
    Publication date: December 5, 2002
    Inventors: H. Andrew Strong, Mohammad Azab Ali, Troy Albert Reaves